Physician profile
Kimberly A Lee
NPI 1205457595
$3,971.20
in general payments reported to CMS, 2019-2025
29 companies · $1,083 in 2025
The $1,083 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $304 · 2023: $1,376 · 2024: $1,208 · 2025: $1,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,668.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,667.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.45 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $394.52 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $339.77 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Otsuka America Pharmaceutical, INC. | $311.50 | 2023-2025 | Rexulti |
| Pfizer INC. | $302.49 | 2022-2025 | |
| Axsome Therapeutics, INC. | $231.95 | 2023-2025 | Auvelity, Sunosi |
| Lilly USA, LLC | $219.27 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $211.32 | 2022-2023 | |
| Exact Sciences Corporation | $177.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $117.00 | 2023-2025 | Caplyta |
| Mylan Specialty L.P. | $111.23 | 2022-2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.33 | 2022-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $78.49 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.50 | 2022-2024 | Jardiance |
| Sumitomo Pharma America, INC. | $63.65 | 2023 | Gemtesa |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $61.73 | 2025 | Watchman Access System |
| Actelion Pharmaceuticals US, INC. | $56.65 | 2024 | Uptravi, Opsumit |
| Amgen INC. | $54.16 | 2023-2025 | Prolia, Evenity, Otezla |
| Harmony Biosciences LLC | $48.39 | 2023-2024 | Wakix |
| E.R. Squibb & Sons, L.L.C. | $47.34 | 2023 | Eliquis |
| Phathom Pharmaceuticals, INC. | $38.85 | 2024 | Voquezna |
| Shield Therapeutics INC | $35.00 | 2023 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $33.29 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.24 | 2025 | Trintellix |
| Dexcom, INC. | $29.18 | 2024 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $17.89 | 2023 | |
| Glaxosmithkline, LLC. | $14.81 | 2024 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $14.64 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.22 | 2023 | Seglentis, Livalo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.